Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CTSD | P07339 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.37 |
| ▸ | S100A10 | P60903 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407500 | 0.84 | L3MBTL1 (0.41) | KDM4EALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL6344365 | 0.78 | MEN1 (0.57) | ALDH1A1L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6407647 | 0.77 | PI4KB (0.34) | KDM4EALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL6408514 | 0.77 | KDM4E (0.36) | KDM4EALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL6403530 | 0.73 | ALDH1A1 (0.49) | KDM4EALDH1A1KMT2ASMN1; SMN2CTSD | |
| SCHEMBL6410963 | 0.72 | RORC (0.37) | KDM4EALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL6410968 | 0.72 | RORC (0.37) | KDM4EALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL6405526 | 0.71 | PKM (0.37) | KDM4EALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL6405533 | 0.71 | PKM (0.37) | KDM4EALDH1A1PKML3MBTL1MEN1 | |
| SCHEMBL6335320 | 0.70 | KMT2A (0.53) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| US-6969713-B2 | Piperidine and piperazine acetamide derivatives | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242427-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046200-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | KDM4E 1104/4885ALDH1A1 187/4885PKM 658/4885 |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | KDM4E 1566/4885ALDH1A1 68/4885PKM 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.